In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1β-methylcarbapenems with potent activities against multiresistant gram-positive bacteria

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2471-2480

  Ueda, Yutaka ^a   Sunagawa, Makoto ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (THIAZOL 2 YLTHIO) 1BETA METHYLCARBAPENEM; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CYCLOPHOSPHAMIDE; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; PENICILLIN DERIVATIVE; PENICILLIN G; SM 197436; SM 232721; SM 232724; UNCLASSIFIED DRUG;

ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTEROIDES FRAGILIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ABSCESS; ACETAMIDES; AMPICILLIN RESISTANCE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CARRIER PROTEINS; DIPEPTIDASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HEXOSYLTRANSFERASES; KIDNEY; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MULTIENZYME COMPLEXES; MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE; OXAZOLIDINONES; PENICILLIN-BINDING PROTEINS; PEPTIDYL TRANSFERASES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0042268094     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2471-2480.2003     Document Type: Article

References (26)

1. Adachi, Y., K. Nakamura, Y. Kato, N. Hazumi, T. Hashizume, and S. Nakagawa. 1997. In vitro evaluation of BO-3482, a novel dithiocarbamate carbapenem with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 41:2282-2285.
2. Chamberland, S., J. Blais, M. Hoang, C. Dinh, D. Cotter, E. Bond, C. Gannon, C. Park, F. Malouin, and M. N. Dudley. 2001. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Antimicrob. Agents Chemother. 45:1422-1430.
3. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1982.
4. Diekema, D. J., M. A. Pfaller, F. J. Schmits, J. Smayevsky, J. Bell, R. N. Jones, M. Beach, et al. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 12):S114-S132.
5. Emori, T. G., and R. P. Gaynes. 1993. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 6:428-442.
6. Fontana, R., M. Aldegheri, M. Ligozzi, H. Lopez, A. Sucari, and G. Satta. 1994. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcusfaecium. Antimicrob. Agents Chemother. 38:1980-1983.
7. Fukasawa, M., Y. Sumita, E. T. Harabe, T. Tanio, H. Nouda, T. Kohzuki, T. Okuda, H. Matsumura, and M. Sunagawa. 1992. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.
8. Fung-Tomic, J. C., J. Clark, B. Minassian, M. Pucci, Y.-H. Tsai, E. Gradelski, L. Lamb, I. Medina, E. Huczko, B. Kolek, S. Chaniewski, C. Ferraro, T. Washo, and D. P. Bonner. 2002. In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against methicillin-resistant and -susceptible staphylococci. Antimicrob. Agents Chemother. 46:971-976.
9. Gonzales, R. D., P. C. Schreckenbergar, M. B. Graham, S. Kelkar, K. Denbesten, and J. P. Quinn. 2001. Infections due to vancornycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1979.
10. Hakenbeck, R., and J. Coyette. 1998. Resistant penicillin-binding proteins. Cell. Mol. Life Sci. 54:332-340.
11. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
12. Jacobs, M. R. 1999. Drug-resistant Streptococcuspneumoniae: rational antibiotic choice. Am. J. Med. 106(Suppl. 5A):19S-25S.
13. Jones, R. N. 2001. Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 119:397S-404S.
14. Lamb, H. M., D. P. Figgitt, and D. Faulds. 1999, Quinupristin/dalfopristin. A review of its use in the management of serious gram-positive infections. Drugs 58:1061-1097.
15. Livermore, D. M. 2000. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother. 46:347-350.
16. Malanoski, G., L. Collins, C. T. Eliopoulos, R. C. Moellering, Jr., and G. M. Elipoulos. 2000. Comparative in vitro activities of L-695, 256, a novel carbapenem, against gram-positive bacteria, Antimicrob. Agents Chemother. 39:990-995.
17. McGowan, J. E., Jr. 2000. The impact of changing pathogens of serious infections in hospitalized patients. Clin. Infect. Dis. 31(Suppl. 4):S124-S130.
18. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721.
19. Nagano, R., K. Shibata, Y. Adachi, H. Imamura, T. Hashizume, and H. Morishima. 2000. In vitro activities of novel trans-3, 5-disubstituted pyrrolidinylthio-1β-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa Antimicrob. Agents Chemother. 44:489-495.
20. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. Ratcliffe, R. W., R. R. Wilkening, K. J. Wildonger, S. T. Waddell, G. M. Santorelli, D. L. Parker, Jr., J. D. Morgan, T. A. Blizzard, M. L. Hammond, J. V. Heck, J. Huber, J. Kohler, K. L. Dorso, E. S. Rose, J. G. Sundelof, W. J. May, and G. G. Hammond. 1999, Synthesis and properties of 2-(naphthosultamyl)methylcarbapenems with potent anti-MRSA activity: discovery of L-786,392. Bioorg. Med. Chem. 9:679-684.
22. Rybak, M. J., and R. L. Akins. 2001. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs 61:1-7.
23. Shinagawa, H., H. Yamaga, H. Houchigai, Y. Sumita, and M. Sunagawa. 1997. Synthesis and biological properties of a new series of anti-MRSA beta-lactams: 2-(thiazol-2-ylthio) carbapenems. Bioorg. Med. Chem. 5:601-621.
24. Sumita, Y., M. Fukasawa, S. Mitsuhashi, and M. Inoue. 1995. Binding affinities of β-lactam antibiotics for penicillin-binding protein 2′ in methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 35:473-481.
25. Sumita, Y., N. Nouda, K. Kanazawa, and M. Fukasawa. 1995. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39:910-916.
26. Sunagawa, M., M. Itoh, K. Kubota, A. Sasaki, Y. Ueda, P. Angehrn, A. Bourson, E. Goetschi, P. Hebeisen, and R. L. Then. 2002. New anti-MRSA and VRE carbapenems: synthesis and structure-activity relationships of 1 β-methyl-2-(thio-2-ylthio)carbapenems. J. Antibiot. (Tokyo) 55:722-757.